

Form PTO-892 U.S. Department of Commerce	Serial Number	Group Art Unit	Attachment to Paper Number	
	<b>09/756,411</b>	<b>1623</b>	<b>09202004</b>	
Notice of References Cited		APPLICANT(S) <b>Lori et al.</b>		

### U. S. Patent Documents

*		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	Filing Date If Appropriate
*	<b>A</b>	<b>4,708,818 A</b>	<b>11/24/87</b>	<b>Montagnier et al.</b>	<b>435</b>	<b>005.000</b>	
*	<b>B</b>	<b>5,026,687 A</b>	<b>06/25/91</b>	<b>Yarchoan et al.</b>	<b>514</b>	<b>045.000</b>	
*	<b>C</b>	<b>5,110,600 A</b>	<b>05/05/92</b>	<b>Green</b>	<b>424</b>	<b>450.000</b>	
*	<b>D</b>	<b>5,300,059 A</b>	<b>04/05/94</b>	<b>Rubinstein et al.</b>	<b>604</b>	<b>408.000</b>	
*	<b>E</b>	<b>5,521,161 A</b>	<b>05/28/96</b>	<b>Malley et al. (I)</b>	<b>514</b>	<b>045.000</b>	
*	<b>F</b>	<b>5,736,526 A</b>	<b>04/07/98</b>	<b>Malley et al. (II)</b>	<b>514</b>	<b>045.000</b>	
*	<b>G</b>	<b>5,736,527 A</b>	<b>04/07/98</b>	<b>Malley et al. (III)</b>	<b>514</b>	<b>045.000</b>	
*	<b>H</b>	<b>6,046,175 A</b>	<b>04/04/20</b>	<b>Lori et al. (I)</b>	<b>514</b>	<b>045.000</b>	
*	<b>I</b>	<b>6,093,702 A</b>	<b>07/25/00</b>	<b>Malley et al. (IV)</b>	<b>514</b>	<b>045.000</b>	
*	<b>J</b>	<b>6,194,390 B1</b>	<b>02/27/01</b>	<b>Lori et al. (II)</b>	<b>514</b>	<b>045.000</b>	
*	<b>K</b>	<b>6,093,702 A</b>	<b>07/25/00</b>	<b>Malley et al. (V)</b>	<b>514</b>	<b>045.000</b>	


### Foreign Patent Documents

*		DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUB-CLASS		
*	<b>L</b>	<b>EP 0,206,497 A2</b>	<b>12/30/86</b>	<b>Europe(EPO)</b>	<b>Wellcome Fndtn</b>	<b>-----</b>	<b>-----</b>		
*	<b>M</b>	<b>W O 87/01284 A1</b>	<b>03/12/87</b>	<b>World(WO/PCT)</b>	<b>US Dept. Commerce</b>	<b>-----</b>	<b>-----</b>		

### Other References (Including Author, Title, Date, Pertinent Pages, etc.)

*	<b>R</b>	<b>Gao et al. (I), "Low Levels of Deoxynucleotides in Peripheral Blood Lymphocytes: A Strategy to Inhibit Human Immunodeficiency Virus Type 1 Replication,"</b> <i>Proc. National Academy Sciences USA, 90, 8925-8928 (October, 1993).</i>							
---	----------	---	--	--	--	--	--	--	--

† Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.


EXAMINER L. E. Crane 	DATE <b>09/18/04</b>	page 1 of 6 ¥: Reference not presently available.
*A copy of this reference is not being furnished with this office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)		

Form PTO-892 U.S. Department of Commerce	Serial Number	Group Art Unit	Attachment to Paper Number
	<b>09/756,411</b>	<b>1623</b>	<b>09202004</b>
Notice of References Cited	APPLICANT(S)  <b>Lori et al.</b>		

**Other References (Including Author, Title, Date, Pertinent Pages, etc.)**

*	<b>S†</b>	<u>Biochemicals/Organic Compounds for Research and Diagnostic Reagents</u> , <b>Sigma Chemical Co.</b> (catalog), St. Louis, MO, 1992, pp. 321, 341-342.
*	<b>T†</b>	<b>Feorino et al.</b> , "Prevention of Activation of HIV-1 by Antiviral Agents in OM-10.1 Cells," <i>Antiviral Chemistry &amp; Chemotherapy</i> , 4(1), 55-63 (1993).
*	<b>U†</b>	<b>Snyder et al. (I)</b> , "Effects of Hydroxyurea and Thymidine Derivatives on the Uptake and Metabolism of Deoxycytidine and Arabinosylcytosine in Log Phase and Contact-Inhibited Human Fibroblasts," <i>Molecular Pharmacology</i> , 28(6), 574-580 (1985); see p. 578 in particular.
*	<b>V</b>	<b>Licastro et al.</b> , "Inhibition of Polymerases- $\alpha$ and - $\beta$ Completely Blocks DNA Repair Induced by UV Irradiation in Cultured Mouse Neuronal Cells," <i>Biochemical Biophysical Res. Comm.</i> , 132(3), 929-933 (Nov. 15, 1985).
*	<b>W†</b>	<b>Busso et al.</b> , "Cellular Pharmacology and Anti-HIV Activity of 2',3'-Dideoxyguanosine," <i>AIDS Res. Human Retroviruses</i> , 6(9), 1139-1146 (1990).
*	<b>X</b>	<b>R. S. Root-Bernstein(I)</b> , "AIDS IS More Than HIV: Part I," <i>Genetic Engineering News</i> , September 1, 1992, pp. 4-6.
*	<b>Y</b>	<b>R. S. Root-Bernstein(II)</b> , "AIDS IS More Than HIV: Part II," <i>Genetic Engineering News</i> , September 15, 1992, pp. 4-5.
*	<b>Z</b>	"Kaposi's Sarcoma and <i>Pneumocystis</i> Pneumonia Among Homosexual Men," <u>Morbidity Mortality Weekly Rept.</u> , Vol. 30(25), <b>Centers for Disease Control</b> , July 3, 1981, pp. 305-308.

† Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.


EXAMINER	DATE	page 2 of 6
L. E. Crane 	<b>09/18/04</b>	¥: Reference not presently available.
*A copy of this reference is not being furnished with this office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)		

Form PTO-892 U.S. Department of Commerce	Serial Number <b>09/756,411</b>	Group Art Unit <b>1623</b>	Attachment to Paper Number <b>09202004</b>	
Notice of References Cited	APPLICANT(S)			
	Lori et al.			

**Other References (Including Author, Title, Date, Pertinent Pages, etc.)**

*	RA†	<b>Barre-Sinoussi et al.</b> , "Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)," <i>Science</i> , 220, 868-871 (1983).
*	SA	<b>Fauci (I)</b> , "The Human Immunodeficiency Virus: Infectivity and Mechanisms of Pathogenesis," <i>Science</i> , 239, 617-622 (February 1988).
*	TA	<b>Fauci (II)</b> , "Multifactoral Nature of Human Immunodeficiency Virus Disease: Implications for Therapy," <i>Science</i> , 262, 1011-1018 (November 12, 1993).
*	UA	<b>Zack et al.</b> , "HIV-1 Entry into Quiescent Primary Lymphocytes: Molecular Analysis Reveals a Labile, Latent Viral Structure," <i>Cell</i> , 61, 213-222 (April 20, 1990).
*	VA	<b>Bukrinsky et al.</b> , "Quiescent T Lymphocytes as an Inducible Virus Reservoir in HIV-1 Infection," <i>Science</i> , 254, 233-237 (October 18, 1991).
*	WA	<b>Schnittman et al.</b> , "The Reservoir for HIV-1 in Human Peripheral Blood Is a T Cell that Maintains Expression of CD4," <i>Science</i> , 245, 305-308 (July, 1989).
*	XA	<b>Fox et al.</b> , "Lymphoid Germinal Centers Are Reservoirs of Human Immunodeficiency Virus Type 1 RNA," <i>Journal of Infectious Diseases</i> , 164, 1051-1057 (December, 1991).
*	YA	<b>Hirsch et al.</b> , "Therapy for Human Immunodeficiency Virus Infection," <i>New England Journal of Medicine</i> , 328(23), 1686-1695 (June 10, 1993).

† Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.


EXAMINER L. E. Crane 	DATE <b>09/18/04</b>	page 3 of 6 ¥: Reference not presently available.
<p align="center">*A copy of this reference is not being furnished with this office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)</p>		

Form PTO-892 U.S. Department of Commerce	Serial Number	Group Art Unit	Attachment to Paper Number	
	<b>09/756,411</b>	<b>1623</b>	<b>09202004</b>	
Notice of References Cited		APPLICANT(S)  <b>Lori et al.</b>		

**Other References (Including Author, Title, Date, Pertinent Pages, etc.)**

* ZA†	<b>Pauwels et al.</b> , "Rapid and Automated Tetrazolium-Based Colorimetric Assay for the Detection of Anti-HIV Compounds," <i>Journal of Virological Methods</i> , 20, 309-321 (1988).
* RB	<b>Yarchoan et al.</b> , "Clinical Pharmacology of 3'-Azido-2', 3'-dideoxythymidine (Zidovudine) and Related Dideoxynucleosides," <i>New England Journal of Medicine</i> , 321(11), 726-738 (September 14, 1989).
* SB†	<b>Chow et al.</b> , "Use of Evolutionary Limitations of HIV-1 Multidrug Resistance to Optimize Therapy," <i>Nature</i> , 361, 650-654 (1993).
* TB	<b>Lori et al.(III)</b> , "Hydroxyurea as an Inhibitor of Human Immunodeficiency Virus-Type 1 Replication," <i>Science</i> , 266, 801-805 (November 4, 1994).
* UB†	<b>Karlsson et al.</b> , "Hydroxyurea Increases the Phosphorylation of 3'-fluorothymidine and 3'-Azidothymidine in CEM Cells," <i>European Journal of Biochemistry</i> , 186, 689-694 (1989).
* VB†	<b>Marquez et al.</b> , "Acid-Stable 2'-Fluoro Purine Dideoxynucleosides as Active Agents Against HIV," <i>Journal of Medicinal Chemistry</i> , 33(3), 978-985 (1990).
* WB†	<b>Snyder et al. (II)</b> , "The Accumulation of DNA Breaks Due to Incision; Comparative Studies with Various Inhibitors," Ch. 2 in <u>DNA Repair et al. r and Its Inhibition</u> , <u>Nucleic Acids Symposium Series No. 13</u> , Collins et al. eds., IRL Press, Oxford, England, 1984, pp. 13-33.

† Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

EXAMINER L. E. Crane 	DATE <b>09/18/04</b>	<b>page 4 of 6</b> ¥: Reference not presently available.
*A copy of this reference is not being furnished with this office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)		

**09/756,411** - PTO-892 Copy for [ ] FILE APPLICANT Attachment to P. N. **09202004**


Form PTO-892 U.S. Department of Commerce	Serial Number <b>09/756,411</b>	Group Art Unit <b>1623</b>	Attachment to Paper Number <b>09202004</b>	
Notice of References Cited	APPLICANT(S) <b>Lori et al.</b>			

**Other References (Including Author, Title, Date, Pertinent Pages, etc.)**

* XB	Vila et al., "Absence of Viral Rebound After Treatment of HIV-Infected Patients with Didanosine [ddI] and Hydroxycarbamide [aka Hydroxyurea]," <i>Lancet</i> , 350(9078), 635-636 (August 30, 1997).
* YB	Schoofs, "The Berlin Patient," <i>The New York Times Magazine</i> , pp. 32-35, June 21, 1998.
* ZB†	Balzarini, J., "Effect of Antimetabolite Drugs of Nucleotide Metabolism on the Anti-Human Immunodeficiency Virus Activity of Nucleoside Reverse Transcriptase Inhibitors," <i>Pharmacology and Therapeutics</i> , 87(2-3), 175-187 (2000).††
* RC†	Gao et al. (II), "Enhancement by Hydroxyurea of the Anti-Human Immunodeficiency Virus Type 1 Potency of 2'- $\beta$ -Fluoro-2',3'-dideoxyadenosine in Peripheral Blood Mononuclear Cells," <i>Biochemical Pharmacology</i> , 50(2), 274-276 (1995).††
* SC†	Masood et al., "2'-Fluoro-2',3'-dideoxyarabinosyladenine: A Metabolically Stable Analogue of the Antiretroviral Agent 2',3'-Dideoxyadenosine," <i>Molecular Pharmacology</i> , 37, 590-596 (1990).
TC†	Hitchcock et al., "Biochemical Pharmacology of 2'-Fluoro-2',3'-dideoxyarabinosyladenine, an Inhibitor of HIV with Improved Metabolic and Chemical Stability over 2',3'-Dideoxyadenosine," <i>Antiviral Chemistry &amp; Chemotherapy</i> , 1, 319-327 (1990).
* UC	Gao et al. (III), "Differential Phosphorylation of Azidothymidine, Dideoxycytidine, and Dideoxyinosine in Resting and Activated Peripheral Blood Mononuclear Cells," <i>Journal of Clinical Investigations</i> , 91(5), 2326-2333 (May, 1993).

† Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

†† Copy kindly supplied by Applicant.

EXAMINER L. E. Crane 	DATE <b>09/18/04</b>	page 5 of 6 ¥: Reference not presently available.
*A copy of this reference is not being furnished with this office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)		

